Edwards Lifesciences (EW) Total Current Liabilities (2009 - 2026)

Edwards Lifesciences' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 1.02% year-over-year to $1.4 billion in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 1.02% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, up 20.5% from the prior year.
• Total Current Liabilities retreated to $1.4 billion in Q1 2026 per EW's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.9 billion in Q3 2024 and bottomed at $917.9 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $1.2 billion (2024), against an average of $1.3 billion.
• Across the five-year window, Total Current Liabilities surged 56.92% in 2024 and declined 18.32% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $1.0 billion in 2022, then advanced by 16.92% to $1.2 billion in 2023, then gained by 25.92% to $1.5 billion in 2024, then rose by 20.5% to $1.8 billion in 2025, then declined by 22.31% to $1.4 billion in 2026.
• Per Business Quant, the three latest EW Total Current Liabilities figures stand at $1.4 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.6 billion (Q3 2025).